Sophia Genetics Closes $77M Funding Round

Jan 04, 2019 | staff reporter

NEW YORK (GenomeWeb) – Sophia Genetics said today that it has closed on a $77 million Series E round of venture capital, led by new investor Generation Investment Management, with participation from Idinvest Partners and previous Sophia equity backers Balderton Capital and Alychlo.

Sophia, which now has co-headquarters in Boston and Lausanne, Switzerland, said that it will apply much of the new funding to expand its US presence by growing its workforce and marketing to more American hospitals.

"With Generation’s support, we will enable the more rapid adoption of data-driven medicine technology in healthcare for the benefit of patients worldwide," added Sophia CEO and Founder Jurgi Camblong.

Sophia Genetics last landed new funding in a $30 million Series D round that closed in September 2017. To date, the company has raised $140 in private equity.

Filed under

software developers

artificial intelligence

machine learning

Sophia Genetics

equity investment

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.